By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


Laurantis Pharma Oy 

Itäinen Pitkäkatu 4 B
  FI-20520  Turku  Finland
Phone: 358-0-2-4788-378 Fax: 358-0-2-4788-371



Company News
Laurantis Pharma Oy and Ark Therapeutics Sign Manufacturing Agreement for Production of Lymfactin™ Investigational Treatment for Breast Cancer-Associated Lymphedema 10/15/2012 9:07:15 AM
Laurantis Pharma Oy Issued Patent for Cis-UCA as a Treatment for Bladder Cancer 10/9/2012 9:53:10 AM
Laurantis Pharma Oy Completes Funding Round for Research Program 9/4/2012 9:18:01 AM
U.S. Patent Office Allows Laurantis Pharma Oy Application for Treatment of Skin Inflammation 8/1/2012 8:46:28 AM
Laurantis Pharma Oy Release: Investigational Cis-urocanic Acid Eye Drops for Dry Eye Syndrome Well Tolerated, in Phase 1 Clinical Study 6/28/2012 9:23:51 AM
Laurantis Pharma Oy Release: Research Team Discovers Four-Fold Improvement in Ability to Restore Lymphatic Function With Adenovirally-Delivered VEGF-C Gene Therapy After Lymph Node Transplant Surgery Compared to the Surgery Alone 3/7/2012 8:44:43 AM
Laurantis Pharma Oy Release: New Treatment for Lymphedema Could Mean Breakthrough for Breast Cancer Patients 9/22/2011 12:07:06 PM